Song T, Wu KH, Yang H, Xie WL, Shen L. Multidisciplinary treatment strategies for the assessment of immune, coagulation, and biomarker responses after transarterial chemoembolization for hepatocellular carcinoma. World J Gastrointest Surg 2025; 17(5): 101605 [DOI: 10.4240/wjgs.v17.i5.101605]
Corresponding Author of This Article
Tian Song, Associate Chief Physician, Department of Radiology, Hua Dong Hospital, Fudan University, No. 221 West Yan’an Road, Jing’an District, Shanghai 200040, China. st13032174848@163.com
Research Domain of This Article
Radiology, Nuclear Medicine & Medical Imaging
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. May 27, 2025; 17(5): 101605 Published online May 27, 2025. doi: 10.4240/wjgs.v17.i5.101605
Multidisciplinary treatment strategies for the assessment of immune, coagulation, and biomarker responses after transarterial chemoembolization for hepatocellular carcinoma
Tian Song, Kan-Hua Wu, Hao Yang, Wen-Li Xie, Lan Shen
Tian Song, Kan-Hua Wu, Hao Yang, Wen-Li Xie, Lan Shen, Department of Radiology, Hua Dong Hospital, Fudan University, Shanghai 200040, China
Co-first authors: Tian Song and Kan-Hua Wu.
Author contributions: Song T, Wu KH and Yang H designed this study; Song T, Wu KH, Xie WL and Shen L analyzed the data; Song T and Wu KH wrote manuscript and contributed equally as co-first authors; and all authors read and approved the final manuscript.
Institutional review board statement: This study was approved by the Ethic Committee of Hua Dong Hospital, Fudan University.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tian Song, Associate Chief Physician, Department of Radiology, Hua Dong Hospital, Fudan University, No. 221 West Yan’an Road, Jing’an District, Shanghai 200040, China. st13032174848@163.com
Received: December 20, 2024 Revised: February 6, 2025 Accepted: March 18, 2025 Published online: May 27, 2025 Processing time: 153 Days and 18.5 Hours
Core Tip
Core Tip: Given the suboptimal efficacy of single-treatment modalities for hepatocellular carcinoma (HCC) patients, this study proposes comprehensive multidisciplinary treatment strategies for HCC patients post-transarterial chemoembolization (TACE). Through multidimensional assessments including patient characteristics, short-term efficacy and safety evaluations, as well as immune, coagulation, and tumor biomarker responses, the study demonstrates that the multidisciplinary approach enhances treatment outcomes, improves immune responses and coagulation functions, reduces tumor biomarker levels, and decreases the risk of adverse reactions in post-TACE HCC patients. These findings contribute to the development of more favorable treatment strategies for improving survival outcomes in HCC patients post-TACE and may offer more effective clinical guidance for implementing multidisciplinary treatment or nursing strategies.
